[go: up one dir, main page]

ES2634613T3 - Métodos de obtención de leche estéril y composiciones de la misma - Google Patents

Métodos de obtención de leche estéril y composiciones de la misma Download PDF

Info

Publication number
ES2634613T3
ES2634613T3 ES07811645.6T ES07811645T ES2634613T3 ES 2634613 T3 ES2634613 T3 ES 2634613T3 ES 07811645 T ES07811645 T ES 07811645T ES 2634613 T3 ES2634613 T3 ES 2634613T3
Authority
ES
Spain
Prior art keywords
protein
fraction
milk
whole milk
skimmed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07811645.6T
Other languages
English (en)
Inventor
Elena Maria Medo
Armando Montoya
Martin L. Lee
David Rechtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prolacta Bioscience Inc
Original Assignee
Prolacta Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolacta Bioscience Inc filed Critical Prolacta Bioscience Inc
Application granted granted Critical
Publication of ES2634613T3 publication Critical patent/ES2634613T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/20Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A23C9/206Colostrum; Human milk
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23BPRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B11/00Preservation of milk or dairy products
    • A23B11/10Preservation of milk or milk preparations
    • A23B11/12Preservation of milk or milk preparations by heating
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/14Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1422Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of milk, e.g. for separating protein and lactose; Treatment of the UF permeate
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C2210/00Physical treatment of dairy products
    • A23C2210/25Separating and blending
    • A23C2210/252Separating a milk product in at least two fractions followed by treatment of at least one of the fractions and remixing at least part of the two fractions

Landscapes

  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Health & Medical Sciences (AREA)
  • Water Supply & Treatment (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dairy Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un método para la obtención de una composición de leche humana que comprende: (a) filtración de leche entera agrupada a través de un filtro de 100-400 micrómetros; (b) tratamiento térmico de la leche entera a 58-65 °C durante 20-40 minutes; (c) separación de la leche entera en una porción desnatada y una porción de grasa; (d) ultrafiltración de la porción desnatada a través de uno o más ultrafiltros para obtener una porción permeada y una fracción retenida desnatada rica en proteínas; (e) mezclado de una fracción de la porción de grasa con la fracción retenida desnatada rica en proteínas para obtener una composición de leche humana.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
12
imagen12
imagen13
imagen14

Claims (11)

  1. REIVINDICACIONES
    1. Un método para la obtención de una composición de leche humana
    que comprende: 5
    (a)
    filtración de leche entera agrupada a través de un filtro de 100-400 micrómetros;
    (b)
    tratamiento térmico de la leche entera a 58-65 °C durante 20-40 minutes;
    (c)
    separación de la leche entera en una porción desnatada y una porción de grasa;
    (d) ultrafiltración de la porción desnatada a través de uno o más ultrafiltros para obtener una porción permeada y 10 una fracción retenida desnatada rica en proteínas;
    (e) mezclado de una fracción de la porción de grasa con la fracción retenida desnatada rica en proteínas para obtener una composición de leche humana.
  2. 2. El método de la reivindicación 1, que comprende además el análisis de una muestra de la leche entera para 15 determinar la presencia de VIH1, VIH2, VHB, VHC, HTLVI, HTLVII, sífilis y B. cereus antes de la filtración.
  3. 3. El método de la reivindicación 1, en el que el filtrado de la leche entera en la etapa (a) se realiza a través de un tamiz de filtro de 200 micrómetros.
    20 4. El método de la reivindicación 1, en el que el tratamiento térmico de la leche entera en la etapa (b) se realiza a 63 °C durante 30 minutos.
  4. 5. El método de la reivindicación 1 en el que la porción de grasa obtenida en la etapa (c) se sigue procesando para
    obtener una porción de leche desnatada adicional. 25
  5. 6. El método de la reivindicación 5, en el que la porción desnatada adicional se agrupa con la porción desnatada obtenida en la etapa (c).
  6. 7. El método de la reivindicación 1, que comprende además recoger y filtrar la fracción permeada obtenida en la 30 etapa (d) para obtener una segunda fracción retenida.
  7. 8. El método de la reivindicación 7 en el que la segunda fracción retenida se añade a la primera fracción retenida obtenida en la etapa (d) de la reivindicación 1.
    35 9. El método de la reivindicación 1 en el que la ultrafiltración utiliza una membrana de ultrafiltración que impide el paso de cualquier sustancia con un peso molecular superior a 1-40 kDa.
  8. 10. El método de las reivindicaciones 1 o 7 que comprende además el lavado de los ultrafiltros con la fracción
    permeada obtenida en la etapa (d) de la reivindicación 1 para obtener un lavado de proteína y la adición del lavado 40 de proteína a la fracción retenida desnatada rica en proteína obtenida en la etapa (d).
  9. 11. El método de la reivindicación 1 en el que tras la pasteurización, se analiza la leche pasteurizada para determinar el contenido nutricional, el contenido de proteínas, los factores específicos y se ajusta a un nivel deseado.
    45
  10. 12. El método de la reivindicación 1, en el que se pasteuriza la composición de leche humana obtenida en la etapa (e).
  11. 13. Una composición de leche humana obtenida según el método de una cualquiera de las reivindicaciones 50 anteriores que comprende:
    (a)
    un constituyente de proteína de 20-70 mg/ml;
    (b)
    un constituyente de grasa de 35-85 mg/ml,
    (c) un constituyente de hidratos de carbono de 70-115 mg/ml. 55
    16
ES07811645.6T 2006-08-30 2007-08-30 Métodos de obtención de leche estéril y composiciones de la misma Active ES2634613T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84137106P 2006-08-30 2006-08-30
US841371P 2006-08-30
US86774806P 2006-11-29 2006-11-29
US867748P 2006-11-29
PCT/US2007/019234 WO2008027572A1 (en) 2006-08-30 2007-08-30 Methods of obtaining sterile milk and compositions thereof

Publications (1)

Publication Number Publication Date
ES2634613T3 true ES2634613T3 (es) 2017-09-28

Family

ID=39136247

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07811645.6T Active ES2634613T3 (es) 2006-08-30 2007-08-30 Métodos de obtención de leche estéril y composiciones de la misma

Country Status (6)

Country Link
US (8) US9149052B2 (es)
EP (1) EP2063722B1 (es)
JP (2) JP5448819B2 (es)
ES (1) ES2634613T3 (es)
PT (1) PT2099321T (es)
WO (1) WO2008027572A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182243A1 (en) 2001-05-14 2002-12-05 Medo Elena Maria Method of producing nutritional products from human milk tissue and compositions thereof
WO2007035870A2 (en) 2005-09-20 2007-03-29 Prolacta Bioscience, Inc. A method for testing milk
DK3485742T3 (da) 2006-11-29 2021-11-15 Prolacta Bioscience Inc Modermælkssammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
US8377445B2 (en) 2006-12-08 2013-02-19 Prolacta Bioscience, Inc. Compositions of human lipids and methods of making and using same
CN102300575A (zh) * 2008-12-02 2011-12-28 普罗莱克塔生物科学公司 人乳渗透物组合物及其制备和使用方法
DK2739157T3 (en) 2011-08-03 2018-01-08 Prolacta Bioscience Inc Microfiltration of human milk to reduce bacterial contamination
US9781947B2 (en) * 2011-10-18 2017-10-10 Nestec S.A. Composition for use in the promotion of magnesium absorption and/or magnesium retention
US9458230B2 (en) * 2013-01-04 2016-10-04 Wisconsin Alumni Research Foundation Secretory IGA compositions, methods of making and methods of use thereof
CN105246342A (zh) 2013-03-13 2016-01-13 普罗莱克塔生物科学公司 高脂人乳产品
US20140271980A1 (en) * 2013-03-13 2014-09-18 Prolacta Bioscience Adulteration testing of human milk
ITMI20131690A1 (it) * 2013-10-14 2015-04-15 Consiglio Nazionale Ricerche Composizione alimentare.
AU2015374053B2 (en) * 2014-12-30 2020-04-09 Prolacta Bioscience, Inc. Methods of preventing and treating bronchopulmonary dysplasia using high fat human milk products
SG11201805635RA (en) 2015-12-30 2018-07-30 Prolacta Bioscience Inc Human milk products useful in pre- and post-operative care
JP7458187B2 (ja) * 2016-10-04 2024-03-29 ラクタロジックス, インコーポレイテッド 滅菌人乳製品を生成するための方法およびシステム
WO2020123121A1 (en) * 2018-12-11 2020-06-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of screening antibodies for treating and/or preventing necrotizing enterocolitis (nec)
US20230248011A1 (en) * 2019-02-07 2023-08-10 Saurin Enterprises PL Human milk fortifier
EP3927171A4 (en) 2019-02-22 2022-11-30 Aquero Canada Ltd. ENRICHED MILK COMPOSITIONS AND METHODS FOR PREPARING THEM
BR112022005578A2 (pt) 2019-09-24 2022-09-20 Prolacta Bioscience Inc Composições e métodos para tratamento de doenças inflamatórias e imunes
WO2022148549A1 (en) 2020-01-14 2022-07-14 Babylat Gmbh Apparatus and method for obtaining protein-enriched fractions from breast milk
WO2021146561A1 (en) 2020-01-17 2021-07-22 Prolacta Bioscience, Inc. Feeding protocol for optimal growth of preterm infants
CN116322371A (zh) 2020-08-14 2023-06-23 普罗莱克塔生物科学公司 与细菌疗法一起使用的人乳寡糖组合物
MX2023008227A (es) 2021-01-12 2023-07-20 Prolacta Bioscience Inc Regimenes de tratamiento simbiotico.
AU2022211396A1 (en) 2021-01-22 2023-06-29 Prolacta Bioscience, Inc. Topical human milk formulations
WO2024130119A2 (en) 2022-12-16 2024-06-20 Prolacta Bioscience, Inc. Synbiotic compositions for short chain fatty acid production

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2148100A (en) * 1936-07-01 1939-02-21 M & R Dietetic Lab Inc Treatment of milk fluids
JPS5948964B2 (ja) * 1978-01-11 1984-11-30 雪印乳業株式会社 人乳に類似した育児用乳の製造法
JPS6133895Y2 (es) * 1980-02-29 1986-10-03
US4462932A (en) * 1983-06-22 1984-07-31 Purdue Research Foundation Isolation of native casein by cryodestabilization
JPS6467141A (en) * 1987-09-08 1989-03-13 Kougakushiya Kk Method for removing various germs and somatic cell from cow's milk and apparatus therefor
JP3061649B2 (ja) * 1991-02-08 2000-07-10 森永乳業株式会社 抗アレルギー性調製乳
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
JP3150504B2 (ja) * 1993-02-26 2001-03-26 雪印乳業株式会社 低乳糖乳製品およびその製造方法
DE4424935C1 (de) * 1994-07-14 1996-03-21 Immuno Ag Humanes virussicheres monomeres Immunglobulin A und Verfahren zu seiner Herstellung
US5670196A (en) * 1995-04-12 1997-09-23 Galagen Inc. Method for microfiltration of milk or colostral whey
JPH09275897A (ja) * 1996-04-16 1997-10-28 Takamichi Tominaga ミルクの調整法及び粉ミルク計量器及び粉ミルク計量器の組合せ
US6194009B1 (en) * 1996-11-22 2001-02-27 Princeton Nutrition, Llc Refrigeration-shelf-stable ultra-pasteurized or pasteurized infant formula
US6652900B2 (en) * 1997-03-14 2003-11-25 Tetra Laval Holdings & Finance S.A. Method and plant for producing a sterile milk product
NL1010829C2 (nl) * 1998-12-16 2000-06-19 Prolion Bv Inrichting en werkwijze voor het melken van dieren en een vervuilingsmeter.
US6294206B1 (en) * 1999-04-09 2001-09-25 Abbott Laboratories Powdered human milk fortifier
EP1233976A4 (en) * 1999-11-17 2003-06-11 Jiuping Ji SIMULTANEOUS DETECTION OF HBV, HCV AND HIV IN PLASMA SAMPLES WITH THE AID OF A MULTIPLEX FIXING TEST
US6932967B2 (en) * 2001-03-22 2005-08-23 Michael R. Simon Human medical treatment by aerosol inhalation of immunoglobulin A
AU2002311897A1 (en) * 2001-05-09 2002-11-18 Third Wave Technologies, Inc. Nucleic acid detection in pooled samples
US20020182243A1 (en) * 2001-05-14 2002-12-05 Medo Elena Maria Method of producing nutritional products from human milk tissue and compositions thereof
PT1474003E (pt) * 2002-02-04 2008-02-29 Bristol Myers Squibb Co Suplemento para leite humano
FI115752B (fi) * 2002-05-14 2005-07-15 Valio Oy Menetelmä käytettäväksi vähälaktoosisen tai laktoosittoman maitotuotteen valmistamiseksi
NZ527434A (en) * 2003-08-07 2006-03-31 Fonterra Co Operative Group Production of protein composition from a dairy stream and its use as an ingredient in the manufacture of a cheese
JP2008512656A (ja) * 2004-09-10 2008-04-24 メデラ ホールディング アーゲー 人乳の分析及び処理方法とそのためのシステム
EP1637043A1 (en) * 2004-09-17 2006-03-22 Medela Holding AG Human milk fortifiers and methods for their production
US20080187619A1 (en) * 2004-09-10 2008-08-07 Medela Holding Ag Human Milk Fortifiers and Methods for Their Production

Also Published As

Publication number Publication date
PT2099321T (pt) 2017-07-21
EP2063722A4 (en) 2011-05-18
WO2008027572A1 (en) 2008-03-06
US20190075809A1 (en) 2019-03-14
US20190327994A1 (en) 2019-10-31
JP5448819B2 (ja) 2014-03-19
US20190053508A1 (en) 2019-02-21
US20160050949A1 (en) 2016-02-25
US9149052B2 (en) 2015-10-06
JP2012231793A (ja) 2012-11-29
US20220232844A1 (en) 2022-07-28
EP2063722A1 (en) 2009-06-03
EP2063722B1 (en) 2017-05-03
US20250185679A1 (en) 2025-06-12
JP5770690B2 (ja) 2015-08-26
JP2010502186A (ja) 2010-01-28
US20110256269A1 (en) 2011-10-20
US20170347675A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
ES2634613T3 (es) Métodos de obtención de leche estéril y composiciones de la misma
Giangrande Six characters in search of an author: the history of the nomenclature of coagulation factors.
Burt et al. Does low birthweight increase the risk of caries? A systematic review
ES2529567T3 (es) Procedimiento de fraccionamiento de composiciones lácteas
ES2234552T3 (es) Un metodo para tratamiento de calostro.
EP2972312A1 (en) Adulteration testing of human milk
Emektar et al. Determination of factors associated with perforation in patients with geriatric acute appendicitis
Garrido-Castañé et al. Cardiopulmonary helminths in foxes from the Pyrenees
Kara et al. Various clinical conditions can mimic Crimean-Congo hemorrhagic fever in pediatric patients in endemic regions
Prasongwatana et al. Chemical components of urinary stones according to age and sex of adult patients
US10694768B2 (en) Process for preparing a soluble protein composition
Mahmud et al. Anemia characteristics after renal transplantation
Salim et al. Oral findings, salivary creatinine and urea levels in CKD patients on hemodialysis and on conservative treatment
Karjoo et al. Review of natural history, benefits and risk factors pediatric liver transplantation
Porter Remarks on intestinal parasites in Montreal, and the relation of Entamoeba histolytica to colitis
Stoiber et al. Whole blood, plasma viscosity, and erythrocyte aggregation as a determining factor of competitiveness in standard bred trotters
Calabrese et al. Review and practical excursus of the propensity score: low protein diet compared to Mediterranean diet in patients with chronic kidney disease
Jorfizadeh et al. Relationships of Students’ Mental Well-being with Mothers’ Emotional Breakdown and Marital Justice Mediated by Mothers’ Marital Intimacy
Martha et al. A Prospective Study of Clinical Profile in Febrile Illness with Thrombocytopenia in Children Aged 1 to 12 Years Admitted in a Tertiary Care Centre in Telangana
Souto et al. Arteritis, aneurysm and thromboembolic colic caused by migration of Strongylus vulgaris larvae in equids
Sangani et al. Prevalence of Intestinal Parasites in a Tertiary Care Hospital in Rural Areas of Dahod.
Ghasemikhah et al. Echinococcosis in livestock slaughtered in arak industrial abattoir in Central Iran during 2006 to 2012
Al-Hajjaj Massive pulmonary hemorrhage in a Saudi female with primary antiphospholipid syndrome
Saeed et al. Cysticercus bovis induced hemato-biochemical changes in cattle and buffaloes.
Krautzig et al. Bacterial challenge of NISSHO ultrafilter ETF 609: Results of in vitro testing